BR112014018575A2 - polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) - Google Patents
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)Info
- Publication number
- BR112014018575A2 BR112014018575A2 BR112014018575A BR112014018575A BR112014018575A2 BR 112014018575 A2 BR112014018575 A2 BR 112014018575A2 BR 112014018575 A BR112014018575 A BR 112014018575A BR 112014018575 A BR112014018575 A BR 112014018575A BR 112014018575 A2 BR112014018575 A2 BR 112014018575A2
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptides
- gdf
- gdf15
- differentiation factor
- growth differentiation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
resumo polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) polipeptídeos gdf15, constructos compreendendo gdf15 e mutantes dos mesmos são fornecidos. em várias modalidades os polipeptídeos gdf15, constructos compreendendo gdf15 e mutantes dos mesmos podem ser de uso no tratamento ou na melhora de um distúrbio metabólico. em várias modalidades a doença ou distúrbio metabílico é diabetes tipo 2, obesidade, dislipidemia, níveis de glicose elevados, níveis de insulina elevados e nefropatia diabética.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261591161P | 2012-01-26 | 2012-01-26 | |
PCT/US2013/023465 WO2013113008A1 (en) | 2012-01-26 | 2013-01-28 | Growth differentiation factor 15 (gdf-15) polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014018575A2 true BR112014018575A2 (pt) | 2017-07-04 |
Family
ID=48873999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014018575A BR112014018575A2 (pt) | 2012-01-26 | 2013-01-28 | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
Country Status (13)
Country | Link |
---|---|
US (3) | US9714276B2 (pt) |
EP (2) | EP2807266B1 (pt) |
JP (1) | JP2015506373A (pt) |
KR (1) | KR20140125803A (pt) |
CN (1) | CN104204218A (pt) |
AU (1) | AU2013211846A1 (pt) |
BR (1) | BR112014018575A2 (pt) |
CA (1) | CA2862745A1 (pt) |
EA (1) | EA201491413A1 (pt) |
IL (1) | IL233725A0 (pt) |
MX (1) | MX2014009129A (pt) |
SG (1) | SG11201404405UA (pt) |
WO (1) | WO2013113008A1 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US20150239968A1 (en) | 2012-09-26 | 2015-08-27 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) |
WO2014120619A2 (en) * | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
MX2015014438A (es) | 2013-04-18 | 2016-05-18 | Armo Biosciences Inc | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. |
EP3434277A1 (en) | 2013-06-17 | 2019-01-30 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
PL3027642T3 (pl) * | 2013-07-31 | 2021-01-11 | Amgen Inc. | Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) |
CA2920679A1 (en) | 2013-08-30 | 2015-03-05 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
AU2014346537A1 (en) | 2013-11-11 | 2016-05-19 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
LT3122775T (lt) | 2014-03-26 | 2020-02-10 | Julius-Maximilians-Universität Würzburg | Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf-15), ir jų panaudojimas vėžinės kachekcijos ir vėžio gydymui |
CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
US10588980B2 (en) * | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
ES2818109T3 (es) * | 2014-06-23 | 2021-04-09 | Novartis Ag | Modificaciones de proteínas específicas para un sitio |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
MX2016016063A (es) * | 2014-06-24 | 2017-03-10 | Novo Nordisk As | Proteinas de fusion de citocina-1 inhibidora de macrofagos (mic-1) y usos de las mismas. |
CN106573966B (zh) * | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
CA2963989A1 (en) | 2014-10-14 | 2016-04-21 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
MX2017004983A (es) | 2014-10-22 | 2017-11-13 | Armo Biosciences Inc | Metodos para usar interleucina 10 para tratar enfermedades y trastornos. |
WO2016069925A1 (en) * | 2014-10-30 | 2016-05-06 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
CA2961587A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US20170334971A1 (en) * | 2014-12-22 | 2017-11-23 | Novo Nordisk A/S | Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
CN107847583A (zh) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | 用于治疗癌症的聚乙二醇化白细胞介素‑10 |
MX2018002298A (es) | 2015-08-25 | 2018-07-06 | Armo Biosciences Inc | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |
HUE060762T2 (hu) | 2015-10-02 | 2023-04-28 | Univ Wuerzburg J Maximilians | Kombinációs terápia humán növekedési és differenciációs faktor 15 (GDF-15) inhibitorokat és immunellenõrzõpont-blokkolókat alkalmazva |
US11262360B2 (en) | 2015-10-02 | 2022-03-01 | Julius-Maximilians-Universität Würzburg | GDF-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers |
EP3393494A1 (en) * | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
CN116732159A (zh) | 2016-01-29 | 2023-09-12 | 勒让德·S·阿普特 | 青光眼中的gdf15及其使用方法 |
IL261666B1 (en) | 2016-03-31 | 2024-05-01 | Ngm Biopharmaceuticals Inc | Related proteins and methods of using them |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
KR101727506B1 (ko) * | 2016-07-14 | 2017-05-04 | 충남대학교 산학협력단 | Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물 |
CA3038846A1 (en) | 2016-10-12 | 2018-04-19 | Janssen Biotech, Inc. | Methods for screening for modulators of gdf15-like biological activity |
CA3045700A1 (en) | 2016-12-06 | 2018-06-14 | St Vincent's Hospital Sydney Limited | Treatment of obesity and eating disorders |
TWI710377B (zh) | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Mic-1化合物及其用途 |
JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー/エス | 肥満の治療において使用するためのmic−1およびglp−1 |
TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
CN111954537A (zh) | 2018-04-09 | 2020-11-17 | 美国安进公司 | 生长分化因子15融合蛋白 |
TW202337914A (zh) * | 2019-04-23 | 2023-10-01 | 南韓商Lg化學股份有限公司 | 融合多肽及其用途與製備方法、核酸分子、重組載體、重組細胞以及用於增強生長/分化因子15或其功能變體的活體內穩定性的方法 |
WO2021067655A1 (en) * | 2019-10-04 | 2021-04-08 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
US20230002460A1 (en) * | 2019-11-26 | 2023-01-05 | Yuhan Corporation | Long-acting gdf15 fusion protein and pharmaceutical composition comprising same |
CN110862436A (zh) * | 2019-12-11 | 2020-03-06 | 浙江鼎持生物制品有限公司 | 一种高效表达非洲猪瘟ep153r蛋白的cho细胞株及其构建方法 |
CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
CN115244076B (zh) * | 2020-10-27 | 2023-08-04 | 北京质肽生物医药科技有限公司 | Gdf15融合蛋白及其用途 |
WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
WO2023025123A1 (zh) * | 2021-08-24 | 2023-03-02 | 广东东阳光药业有限公司 | Gdf15融合蛋白及其用途 |
TW202342014A (zh) | 2022-02-10 | 2023-11-01 | 瑞士商諾華公司 | 1,3-苯并二氧戊環衍生物 |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
SK9432001A3 (en) | 1999-01-07 | 2003-02-04 | Lexigen Pharm Corp | Expression and export of anti-obesity proteins as Fc fusion proteins |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20030103978A1 (en) | 2000-02-23 | 2003-06-05 | Amgen Inc. | Selective binding agents of osteoprotegerin binding protein |
BR0116024A (pt) | 2000-12-07 | 2005-12-13 | Lilly Co Eli | Proteìna de fusão heteróloga e uso da mesma |
US7511121B2 (en) * | 2001-03-09 | 2009-03-31 | Arnason Barry G W | Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
JP4422949B2 (ja) | 2001-06-26 | 2010-03-03 | 武田薬品工業株式会社 | TGF−βスーパーファミリー産生・分泌促進剤 |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
US7101852B2 (en) | 2003-05-30 | 2006-09-05 | The Board Of Regents Of The University Of Texas System | Composition and method for treatment and prevention of restenosis |
WO2005063815A2 (en) * | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
US8846874B2 (en) | 2003-11-13 | 2014-09-30 | Hanmi Science Co., Ltd | IgG Fc fragment for a drug carrier and method for the preparation thereof |
WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
PL2929891T3 (pl) | 2004-04-13 | 2020-08-24 | St Vincent's Hospital Sydney Limited | Sposób modulowania apetytu |
WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
CN1974601A (zh) | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | 一种新型Fc融合蛋白及其生产方法 |
US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
US20100278843A1 (en) * | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
EP2235064B1 (en) | 2008-01-07 | 2015-11-25 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
EP2279419A1 (en) | 2008-05-20 | 2011-02-02 | Roche Diagnostics GmbH | Gdf-15 as biomarker in type 1 diabetes |
JP5787757B2 (ja) * | 2008-08-04 | 2015-09-30 | ファイブ プライム セラピューティックス インコーポレイテッド | Fgfr細胞外ドメイン酸性領域突然変異タンパク質 |
CN102203619B (zh) | 2008-10-31 | 2015-12-16 | 圣文森特医院悉尼有限公司 | 慢性肾病中的预测方法 |
CA2781539C (en) | 2009-11-23 | 2021-07-20 | Amgen Inc. | Monomeric antibody fc |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
JP2013512672A (ja) * | 2009-12-02 | 2013-04-18 | アムジエン・インコーポレーテツド | ヒトFGFR1c、ヒトβ−クロト−、ならびにヒトFGFR1cおよびヒトβ−クロト−の両方に結合する結合タンパク質 |
WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
WO2012007869A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
US9096500B2 (en) | 2010-07-12 | 2015-08-04 | Pfizer Limited | Acyl sulfonamide compounds |
CA2804351A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP3225994A1 (en) | 2010-08-26 | 2017-10-04 | Roche Diagnostics GmbH | Use of biomarkers in the assessment of the early transition from arterial hypertension to heart failure |
EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
JP6167040B2 (ja) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計 |
JP6251040B2 (ja) | 2011-03-15 | 2017-12-27 | エムケイエス インストゥルメンツ, インコーポレイテッド | 液体から溶解ガスを選択的に除去するためのシステムおよび方法 |
EP2686345B1 (en) | 2011-03-16 | 2018-04-25 | Amgen Inc. | Fc variants |
WO2012138919A2 (en) | 2011-04-08 | 2012-10-11 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
BR112014018575A2 (pt) * | 2012-01-26 | 2017-07-04 | Amgen Inc | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
JP6393255B2 (ja) * | 2012-04-20 | 2018-09-19 | メルス ナムローゼ フェンノートシャップ | ヘテロ二量体のIgG様分子を生産する方法、ヘテロ二量体のIgG様分子、ヘテロ二量体の抗体、組み換え宿主細胞、医薬組成物、宿主細胞を作成する方法、および培養物 |
ES2791183T3 (es) | 2012-12-21 | 2020-11-03 | Aveo Pharmaceuticals Inc | Anticuerpos anti-GDF15 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
WO2014120619A2 (en) | 2013-01-30 | 2014-08-07 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use in treating metabolic disorders |
PL3027642T3 (pl) | 2013-07-31 | 2021-01-11 | Amgen Inc. | Konstrukty czynnika różnicowania wzrostu 15 (GDF-15) |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
CN106573966B (zh) | 2014-07-30 | 2022-03-01 | Ngm生物制药有限公司 | 用于治疗代谢异常的组合物和方法 |
CA2961587A1 (en) | 2014-10-31 | 2016-05-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AU2017228489A1 (en) | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
-
2013
- 2013-01-28 BR BR112014018575A patent/BR112014018575A2/pt not_active IP Right Cessation
- 2013-01-28 EA EA201491413A patent/EA201491413A1/ru unknown
- 2013-01-28 EP EP13741489.2A patent/EP2807266B1/en active Active
- 2013-01-28 KR KR1020147023309A patent/KR20140125803A/ko not_active Application Discontinuation
- 2013-01-28 SG SG11201404405UA patent/SG11201404405UA/en unknown
- 2013-01-28 WO PCT/US2013/023465 patent/WO2013113008A1/en active Application Filing
- 2013-01-28 MX MX2014009129A patent/MX2014009129A/es unknown
- 2013-01-28 EP EP20151691.1A patent/EP3683228A3/en active Pending
- 2013-01-28 CN CN201380006982.9A patent/CN104204218A/zh active Pending
- 2013-01-28 US US14/374,885 patent/US9714276B2/en active Active
- 2013-01-28 CA CA2862745A patent/CA2862745A1/en not_active Abandoned
- 2013-01-28 AU AU2013211846A patent/AU2013211846A1/en not_active Abandoned
- 2013-01-28 JP JP2014554933A patent/JP2015506373A/ja active Pending
-
2014
- 2014-07-21 IL IL233725A patent/IL233725A0/en unknown
-
2017
- 2017-06-16 US US15/625,891 patent/US10336798B2/en active Active
-
2019
- 2019-05-17 US US16/416,050 patent/US11739131B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9714276B2 (en) | 2017-07-25 |
EP3683228A2 (en) | 2020-07-22 |
JP2015506373A (ja) | 2015-03-02 |
US11739131B2 (en) | 2023-08-29 |
MX2014009129A (es) | 2014-11-21 |
US20190315822A1 (en) | 2019-10-17 |
EP2807266B1 (en) | 2020-01-15 |
CA2862745A1 (en) | 2013-08-01 |
IL233725A0 (en) | 2014-09-30 |
AU2013211846A1 (en) | 2014-08-14 |
CN104204218A (zh) | 2014-12-10 |
EP3683228A3 (en) | 2020-07-29 |
WO2013113008A1 (en) | 2013-08-01 |
US20140378665A1 (en) | 2014-12-25 |
EA201491413A1 (ru) | 2015-03-31 |
EP2807266A4 (en) | 2016-06-22 |
SG11201404405UA (en) | 2014-08-28 |
US20170291929A1 (en) | 2017-10-12 |
US10336798B2 (en) | 2019-07-02 |
EP2807266A1 (en) | 2014-12-03 |
KR20140125803A (ko) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014018575A2 (pt) | polipetídeos de fator de diferenciação de crescimento 15 (gdf-15) | |
BR112016002213A2 (pt) | Construtos do fator 15 de diferenciação de crescimento (gdf-15) | |
BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
CY1121042T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
MX2013011726A (es) | Metodo de tratamiento o mejoramiento de transtornos metabolicos usando el factor de diferenciacion de crecimiento 15 (gdf-15). | |
BR112015027528A2 (pt) | polipeptídeo, combinação farmacêutica, métodos de tratamento de um distúrbio metabólico e de obesidade, uso de um polipeptídeo ou de uma combinação farmacêutica, molécula de ácido nucleico, vetor de expressão, e, célula hospedeira | |
CL2009000018A1 (es) | Analogo de la insulina con tiempo de accion plano y prolongado; procedimiento de preparación; uso para tratar diabetes mellitus; producto farmaceutico y formulacion que lo comprende; secuencia nucleotidica que lo codifica; vector; y célula hospedera. | |
EA201590715A1 (ru) | Производные эксендина-4 как двойные агонисты glp1/глюкагона | |
JP2014511863A5 (pt) | ||
BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
WO2013033452A3 (en) | Fgf21 for use in treating type 1 diabetes | |
NZ596037A (en) | Fgf21 mutants and uses thereof | |
CL2011000899A1 (es) | Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre. | |
EA201370126A1 (ru) | Человеческие антитела к рецептору глюкагона | |
EA201590011A1 (ru) | Пептидные аналоги эксендина-4 | |
BR112018012833A2 (pt) | método de tratamento ou amenização de distúrbios metabólicos usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas do glp-1 | |
MX2015014007A (es) | Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de accion prolongada. | |
BRPI0908544A2 (pt) | derivados de pirazinona como estimuladores de secreção de insulina, métodos para obtenção dos mesmos, e uso dos mesmos para o tratamento de diabetes | |
BR112013030171A2 (pt) | composição comestível, método para reduzir a amplitude de pico de glicose pós-prandial no sangue ou resposta glicêmica em uma pessoa não diabética, método para tratar uma pessoa com necessidade de tratamento para diabetes do tipo 2 e uso da composição | |
CL2012001972A1 (es) | Compuestos derivados de oxazol[5,4-d]pirimidina sustituidas; procedimiento de preparacion; composicion farmaceutica; utiles en el tratamiento de trastornos en la curacion de heridas en pacientes con diabetes. | |
BR112015001885A2 (pt) | super agonistas de ação longa de hormônio glicoproteína | |
Esposito et al. | Comment on Home et al. Predictive and Explanatory Factors of Change in HbA1c in a 24-Week Observational Study of 66,726 People With Type 2 Diabetes Starting Insulin Analogs. Diabetes Care 2014; 37: 1237–1245 | |
Marslin et al. | Corrigendum to" PEGylated ofloxacin nanoparticles render strong antibacterial activity against many clinically important human pathogens"[Colloids Surf. B: Biointerfaces 132 (2015) 62-70] | |
Wei-Jie | Interpretation of Culture——Luria’s View of Cultural Psychology and Contemporary Psychological Development | |
Ashcheulova et al. | Distant apoptosis markers-FasL (CD95L) and FasR (CD95, APO-1) at hypertensive patients with prediabetes and type 2 diabetes mellitus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |